Company Overview and News
I am projecting AGNC will report a combined modest-notable net unrealized loss on available-for-sale securities and investment securities measured at FMV for the second quarter of 2018.
NYMTO ORC FNMA CHMI NYMTP CIM AI AI.PRB TWO AGNC AIW TWO.PRA TWO.PRB TWO.PRC MO WMC NRZ AIC NLY.PRECL CYS TRI MITT.PRB MITT.PRA CHMI.PRA MITT FMCKI FMCKJ MFA.PRA MFA.PRB CYS.PRA CYS.PRB CIM.PRA FMCCO FMCCP FMCCM IVR.PRA FMCCN IVR.PRB MFO IVR.PRC FMCCI DX NLY NLY.PRA FMCCJ FMCCG FMCKO FMCKP NLY.PRD FMCKM NLY.PRE FMCKN CIM.PRB FMCKK NLY.PRC FMCKL ARR NLY.PRF NLY.PRG MFA FMCC HTS IVR DX.PRB NYMT DX.PRA ARR.PRB ARR.PRA FMCCS FMCCT
Document UNITED STATES
Fairly similar to the prior quarter, I am projecting AGNC will report a modest-notable gain regarding the company’s derivative instruments and other securities for the second quarter of 2018.
CHMI.PRA NYMTO MTGE ORC CHMI NYMTP AI CYS.PRA AI.PRB CYS.PRB TWO AGNC AIW TWO.PRA TWO.PRB TWO.PRC NRZ AIC NLY NLY.PRA NLY.PRECL NLY.PRD NLY.PRE CYS NLY.PRC ARR NLY.PRF NLY.PRG NYMT ARR.PRB ARR.PRA
The performance of 59 securities, which were selected by SA contributors for their high-yield portfolios in 2014, are identified and analyzed for the period May 2014 to July 2018.
AIY AINV ARI PCI RSO.PRBCL NYMTO HTF KAP OSLE NYMTP KCAP FGB AI AI.PRB CMO TWO SDRL HTFA AGNC AIW TWO.PRA SLRA TWO.PRB RSO TWO.PRC WMC AIC NLY.PRECL AIB TCRD PSEC NMFC CYS AIF TSLF MCX SCQ XAN PBB MITT.PRB MITT.PRA RSO.PRA RSO.PRB RSO.PRC SCA RSO.PRACL MCQ HRZN CHW OXLCO MCV OXLCN STWD.WI MITT SCM HTGZ MFA.PRA SLRC MFA.PRB CYS.PRA CYS.PRB BIT MCC TCRX ARCC ARI.PRA GBDC CLMT ARI.PRC MFO DX NLY NLY.PRA TCPC NLY.PRD NLY.PRE TCRZ HTGX OXLC HTGY NLY.PRC ARU OCSL EFC NLY.PRF NLY.PRG MFA DX.PRB NYMT HTGC DX.PRA STWD
This series projects AGNC’s income statement for the second quarter of 2018. These projections help readers understand how most of the fixed-rate agency mREIT sector performed.
CHMI.PRA NYMTO ORC CHMI NYMTP AI CYS.PRA AI.PRB CYS.PRB TWO AGNC AIW TWO.PRA TWO.PRB TWO.PRC NRZ AIC NLY NLY.PRA NLY.PRECL NLY.PRD NLY.PRE CYS NLY.PRC ARR NLY.PRF NLY.PRG HTS NYMT ARR.PRB ARR.PRA
Landmark Infrastructure flaunted top net gains, while Orchid Island Capital had highest yield. Top ten gainers, IVR, TWO,WSR, ORC, EARN, NRZ, DX, CHMI, AJX, & LMRK ranged 10.6%-42.6% 6/28/18.
CHMI.PRA NYMTO ORC CHMI NYMTP CYS.PRA CYS.PRB EARN TWO AGNC TWO.PRA TWO.PRB TWO.PRC AJXA IVR.PRA NRZ IVR.PRB IVR.PRC DX NLY NLY.PRA NLY.PRECL NLY.PRD NLY.PRE CYS NLY.PRC NLY.PRF NLY.PRG IVR DX.PRB NYMT DX.PRA AJX
With a solid balance sheet and an ambitious acquisition strategy, GoodBulk Ltd. (NASDAQ:GBLK) has an interesting business profile. The management seems quite experienced, and the industry is expanding. Plus the fact that Fidelity is among the shareholders will interest the investors. With that, 2017 EBITDA and revenue figures provided show that the shares are expensive at $16.5. Perhaps waiting a few months to receive more information seems to be the right strategy here.
EURN GBLK TWO EURN TWO.PRA TWO.PRB TWO.PRC
Document UNITED STATES
This article compares NLY’s recent dividend per share rates, yield percentages, and several dividend sustainability metrics to twenty mREIT peers.
ANH.PRA ANH.PRC ANH.PRB ANH NYMTO IRC ORC CHMI NYMTP AI AI.PRB CMO TWO AGNC AIW TWO.PRA TWO.PRB GPMT TWO.PRC WMC NRZ AIC NLY.PRECL CYS 511505 CAPITALT MITT.PRB MITT.PRA CHMI.PRA MITT MFA.PRA MFA.PRB CYS.PRA CYS.PRB IVR.PRA IVR.PRB MFO IVR.PRC DX NLY NLY.PRA NLY.PRD NLY.PRE NLY.PRC ARR NLY.PRF BXMT NLY.PRG MFA IVR DX.PRB NYMT DX.PRA ARR.PRB ARR.PRA CMO.PRE
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS
Following continued requests by readers, this article analyzes fixed-rate agency MBS price movements during the second quarter of 2018 (through 6/15/2018).
NYMTO ORC FNMA CHMI NYMTP AI AI.PRB TWO AGNC AIW TWO.PRA TWO.PRB TWO.PRC WMC NRZ AIC NLY.PRECL CYS TRI MITT.PRB MITT.PRA CHMI.PRA MITT FMCKI FMCKJ MFA.PRA MFA.PRB CYS.PRA CYS.PRB FMCCO FMCCP FMCCM IVR.PRA FMCCN IVR.PRB MFO IVR.PRC FMCCI DX NLY NLY.PRA FMCCJ FMCCG FMCKO FMCKP NLY.PRD FMCKM NLY.PRE FMCKN FMCKK NLY.PRC FMCKL ARR NLY.PRF NLY.PRG MFA FMCC IVR DX.PRB NYMT DX.PRA ARR.PRB ARR.PRA FMCCS FMCCT
May 15-June 15, Fredrik Arnold "followers" mentioned 37 equities in their comments and suggestions. Some lamented bad news so bad news stocks mixed in with their favorites.
JE GIS CLA CTL ORC ROYT HCLP JE CYS.PRA CAPL CLNS.PRDCL CJR.B CYS.PRB TWO CPTA TWO.PRA JE.PRA TWO.PRB TWO.PRC MO CLNS CLNS.PRJ CLNS.PRI CLNS.PRH CLNS.PRG CLNS.PRE CLNS.PRD CLNS.PRB CYS FRO CJREF GMLP JNJ
4h - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
2018-07-13 - Asif
Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...
2018-07-09 - Asif
Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...
Silicon Investor Message Boards
This table lists all message boards related to TWO / Two Harbors Investment Corp. on message board site Silicon Investor.
as of ET